According to a new Life Science Intelligence (LSI) report, “2008 Global Vascular Closure Device Markets: U.S., Europe, Rest of World,” the global market for vascular closure devices will reach $868 million in 2013.

The market for vascular closure technologies, which includes implantable devices and external compression products, has traditionally been concentrated in the United States and Western Europe. These technologies are used to replace or augment manual compression following diagnostic catheterizations.

By reducing time to hemostasis and facilitating more rapid recovery, implantable technologies are able to reduce time in the recovery room, which contributes to better patient throughput and higher profits for catheterization labs. External compression products, which include chemically-treated patches, also simplify the process of vascular closure for the clinician and staff.

LSI expects that by 2013, implantable devices and external compression products will account for nearly half of all vascular closures in the U.S., while implantable devices will account for 56 percent of all device-based procedures. In Europe, the use of vascular closure devices in the West has been offset by use of manual compression in the East.
To date, the high cost of implantable vascular closure devices has limited adoption in other international markets. By 2013, however, growing catheterization volumes, better access to new healthcare technologies, an expanding middle class, and the need to increase patient throughput while meeting the standards of Western healthcare will contribute to greater adoption of these technologies. Although only limited use of implantable devices is expected, external compression products, which are significantly less expensive than implantable devices, will experience broader adoption.
For more information, see lsintelligence.com/market-reports-page.php?id=LSI-WW081VA